Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.62 |
| ▸ | C1R | P00736 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 9/20 | 0.43 |
| ▸ | KLK14 | Q9P0G3 | 9/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 9/20 | 0.43 |
| ▸ | CTSG | P08311 | 7/20 | 0.43 |
| ▸ | CTRC | Q99895 | 2/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17554069 | 0.79 | C1R (0.52) | ELANEC1RMEN1KMT2AKLK7 | |
| SCHEMBL12897219 | 0.77 | ELANE (1.00) | ELANEC1RMEN1KMT2APRSS1 | |
| SCHEMBL8216128 | 0.76 | ELANE (1.00) | ELANEC1RKLK7KLK14KLK5 | |
| SCHEMBL17554078 | 0.73 | MAPK1 (0.56) | ELANEKDM4ENPC1ALDH1A1HPGD | |
| SCHEMBL17554026 | 0.72 | ALDH1A1 (0.55) | MEN1KMT2AKLK7KLK14KLK5 | |
| SCHEMBL8068649 | 0.72 | HSD17B10 (0.69) | MEN1KMT2AKDM4ENPC1ALDH1A1 | |
| SCHEMBL8210841 | 0.71 | ELANE (0.78) | ELANEC1R | |
| SCHEMBL12897182 | 0.70 | ELANE (1.00) | ELANEC1R | |
| SCHEMBL12897215 | 0.70 | ELANE (1.00) | ELANEC1R | |
| SCHEMBL708276 | 0.68 | KDM4E (0.69) | ELANEMEN1KMT2AKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872052-B2 | Use of heterocyclic compounds as SCCE inhibitors | AREXIS AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | QUANTUM LTO HOLDINGS, LLC | 2006-11-16 | — | — | US | disclosed |
| US-6180625-B1 | MODULATING AND NORMALIZING AN IMPAIRED HAEMOSTATIC BALANCE IN A MAMMAL, WHICH METHOD COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF NOVEL BENZOXAZIN DERIVATIVES; ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 2001-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258651-A1 | Use of heterocyclic compounds as scce inhibitors | RCE1, CTSE, SPINT2 | ELANE 353/4885C1R 202/4885MEN1 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.